ASCVD
Conditions
Interventions
standard therapy:NA
Evolocumab in combination with standard therapy:NA
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1: Male or female >= 18 to= 85 years of age; 2: Patients or patient’s legally authorized representative has provided informed consent to participate in this study; 3: Patients with established ASCVD prescribed with Repatha in combination with SOC or with SOC alone, according to local guidelines and approved label; 4: Patients with one of the following : A past MI or ischemic stroke plus one of; Event in the past 2 years o Multiple prior events; Documented multivessel coronary disease; Type 2 diabetes mellitus (T2DM) OR Symptomatic peripheral arterial disease (PAD); 5: Most recent prior to enrollment fasting LDL-C >= 70 mg/dL (>= 1.8 mmol/L) or nonhigh- density lipoprotein cholesterol (non-HDL-C) >= 100 mg/dL (>= 2.6 mmol/L); 6: Most recent prior to enrollment fasting TG <= 400 mg/dL (<= 4.5 mmol/L);
Exclusion criteria
Exclusion criteria: 1: Stroke within past 1 month; 2: Past hemorrhagic stroke; 3: Stroke due to thromboembolic event (eg, atrial fibrillation patient without appropriate anticoagulation); 4: Any prior use of Repatha or other PCSK9 inhibition treatments within past 24 weeks; 5: New York Heart Association (NYHA) class III or IV, or last known left ventricular ejection fraction <30%;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CV Endpoint events; | — |
Secondary
| Measure | Time frame |
|---|---|
| LDL-C Change and Percentage Change from Baseline to End of Follow-Up;AE and ADR; | — |
Countries
China
Contacts
Public ContactJianping Li
Peking University First Hospital
Outcome results
None listed